Ansgar Santel
Chief Executive Officer Pantherna Therapeutics
Ansgar Santel is Chief Executive Officer at Pantherna Therapeutics, leading the translation of mRNA therapies into clinical application. With expertise in preclinical mRNA-LNP development and strategic collaborations, he drives innovation in expanding therapeutic indications and advancing next-generation mRNA medicines.
Seminars
Thursday 24th September 2026
Understand & Overcome Liver Tropism to Enable Extrahepatic Delivery
9:00 am
- Analyse biodistribution mechanisms and drivers of liver accumulation
- Modify lipid structure and formulation parameters to shift organ targeting
- Validate targeting strategies in vivo to strengthen translational confidence
Wednesday 23rd September 2026
Introductory Panel: Identify Which LNP Applications Will Deliver Clinical & Commercial Success Across Emerging Modalities
9:00 am
A cross-disciplinary panel bringing together leaders working across the most advanced and emerging applications of LNP delivery, including srRNA, gene editing, in vivo cell therapy, oncology, autoimmune disease and protein replacement.
- Compare delivery requirements across different therapeutic modalities
- Identify where LNPs are already working vs where they are still failing
- Understand how application choice impacts design, toxicity and manufacturability
- Evaluate which areas are overhyped vs commercially viable
- Explore how hybrid systems (lipids, polymers, peptides) are expanding capability
Thursday 24th September 2026
Debate: Which Strategy Will Truly Break Liver Tropism & Enable Clinically Viable Extrahepatic Delivery
11:30 am
3–4 speakers each briefly defend a different approach in this open debate. The audience votes on the most promising strategy.
- Lipid chemistry vs formulation tuning vs hybrid systems
- Passive biodistribution control vs active targeting (ligands, peptides, etc.)
- Incremental optimisation vs completely new delivery paradigms
- What actually translates in vivo vs what only works in preclinical models
